Curocell, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Dalian Wanchun Biotechnology Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Chroma Medicine, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Chengdu Guowei Biopharmaceutical Co. Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Cook MyoSite, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Chengdu Weisijin Biopharmaceutical Technology Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Certest Biotec SL 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

CarryGenes Therapeutics AB 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Cancer Research Technology Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

CDR-Life AG 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Biomica Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Beijing Tiannuo Jiancheng Pharmaceutical Technology Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.